POWDEROUS FORMULATIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS

Stable powderous formulations containing a fat-soluble active ingredient, e.g., vitamin A, in a matrix of a native lupin protein composition are disclosed. 1. Stable powderous formulations comprising a fat-soluble active ingredient in a matrix of a native lupin protein composition wherein the protein is cross-linked.2. Formulations according to claim 1 , wherein the lupin protein composition is a lupin protein isolate having a protein content of more than 90 wt.-%.3. Formulations according to claim 1 , wherein the lupin protein composition is a lupin protein concentrate having a protein content of about 60-90 wt.-%.4. Formulations according to claim 1 , wherein the lupin protein composition is a lupin protein flour having a protein content of about 40-60 wt.-%.5. Formulations according to claim 1 , wherein the native lupin protein composition is selected from the group consisting of a lupin protein isolate having a protein content of more than 90 wt.-% claim 1 , a lupin protein concentrate having a protein content of about 60-90 wt.-% claim 1 , a lupin protein flour having a protein content of about 40-60 wt.-% claim 1 , and mixtures of any of the foregoing.6. Formulations according to claim 1 , wherein the fat-soluble active ingredient is vitamin A claim 1 , D claim 1 , E or K claim 1 , or a carotenoid claim 1 , or a polyunsaturated fatty acid claim 1 , or esters thereof claim 1 , or mixtures thereof.7. Formulations according to claim 1 , wherein the fat-soluble active ingredient is a plant or animal oil or fat claim 1 , particularly sunflower oil claim 1 , palm oil or corn oil.8. Formulations according to claim 1 , comprising additionally a reducing sugar claim 1 , particularly glucose claim 1 , fructose claim 1 , or xylose.9. Formulations according to claim 1 , wherein the protein is cross-linked.10. Food claim 1 , beverages claim 1 , animal feeds claim 1 , cosmetics or drugs comprising a formulation according to .11. A process for the preparation of a ...

POWERED RATCHET WRENCH

A power tool includes a motor having a motor drive shaft, a drive assembly coupled to the motor drive shaft and driven by the motor, an output assembly coupled to the drive assembly and having an output member, and a first housing that houses at least a portion of the motor and at least partially defines an outer surface of the power tool. The first housing is formed from steel for reducing flux losses of the motor. The power tool also includes a second housing disposed around an outer surface of the first housing. The second housing is formed from plastic and includes a grip portion. 1. A power tool comprising:a motor having a motor drive shaft;a drive assembly coupled to the motor drive shaft and driven by the motor;an output assembly coupled to the drive assembly and having an output member; anda housing that houses at least a portion of the motor and at least partially defines an outer surface of the power tool, the housing formed from steel for reducing flux losses of the motor.2. The power tool of wherein the housing includes a first substantially cylindrical portion and a second portion adjacent the first substantially cylindrical portion claim 1 , wherein the first substantially cylindrical portion houses at least a portion of the motor.3. The power tool of wherein the second portion at least partially defines the outer surface of the power tool.4. The power tool of wherein the second portion houses the drive assembly.5. The power tool of wherein the second portion receives the output assembly.6. The power tool of and further comprising a main housing including a grip portion claim 2 , wherein the grip portion at least partially defines another outer surface of the power tool.7. The power tool of wherein the main housing is disposed about an outer circumference of the substantially cylindrical portion of the housing.8. The power tool of wherein the housing further comprises:a first portion at least partially housing the motor;a second portion at least ...

Reformer exercise apparatus

A reformer exercise apparatus is disclosed that has a generally rectangular frame. The rail portions of the frame each have an upright outer wall, an integral downwardly slanted inner wall and a hidden outwardly open slot therein between the outer and inner walls. A foot bar support assembly movably carried by each of the outwardly open slots supports the foot bar. Each foot bar support assembly has an elongated slide plate movably supported within the slot, a hook plate fastened to the slide plate, and a foot bar support arm rotatably and slidably fastened to the hook plate. A pair of tubular risers each having an upper roller therein at the head end of the frame direct arm cord ends to a cord retraction assembly mounted on the carriage. The retraction assembly releases the cords by pivoting either one of the shoulder stops toward the foot end of the frame.

POWDEROUS FORMULATIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS

Stable powderous formulations containing a fat-soluble active ingredient, e.g., vitamin A, in a matrix of a native lupin protein composition are disclosed. 1. Stable powderous formulations comprising a fat-soluble active ingredient in a matrix of a native lupin protein composition wherein the protein is cross-linked.2. Formulations according to claim 1 , wherein the lupin protein composition is a lupin protein isolate having a protein content of more than 90 wt.-%.3. Formulations according to claim 1 , wherein the lupin protein composition is a lupin protein concentrate having a protein content of about 60-90 wt.-%.4. Formulations according to claim 1 , wherein the lupin protein composition is a lupin protein flour having a protein content of about 40-60 wt.-%.5. Formulations according to claim 1 , wherein the native lupin protein composition is selected from the group consisting of a lupin protein isolate having a protein content of more than 90 wt.-% claim 1 , a lupin protein concentrate having a protein content of about 60-90 wt.-% claim 1 , a lupin protein flour having a protein content of about 40-60 wt.-% claim 1 , and mixtures of any of the foregoing.6. Formulations according to claim 1 , wherein the fat-soluble active ingredient is vitamin A claim 1 , D claim 1 , E or K claim 1 , or a carotenoid claim 1 , or a polyunsaturated fatty acid claim 1 , or esters thereof claim 1 , or mixtures thereof.7. Formulations according to claim 1 , wherein the fat-soluble active ingredient is a plant or animal oil or fat claim 1 , particularly sunflower oil claim 1 , palm oil or corn oil.8. Formulations according to claim 1 , comprising additionally a reducing sugar claim 1 , particularly glucose claim 1 , fructose claim 1 , or xylose.9. Formulations according to claim 1 , wherein the protein is cross-linked.10. Food claim 1 , beverages claim 1 , animal feeds claim 1 , cosmetics or drugs comprising a formulation according to .11. A process for the preparation of a ...

Adjustable shoe for a power tool

A band saw includes a first wheel and a second wheel for supporting a continuous band saw blade, a motor operable to drive at least one of the first and second wheels, a housing supporting the first wheel and the second wheel, a shoe for engaging a workpiece, the shoe including a first detent feature. The band saw also includes a second detent feature cooperating with the first detent feature to hold the shoe with respect to the housing. The shoe is moveable with respect to the housing between an engaged position and a non-engaged position. The shoe is moveable out of the engaged position by application of a force acting to move the shoe with respect to the housing sufficient to overcome cooperation between the first and second detent features in the engaged position.

PRO-DRUG FORMING COMPOUNDS

Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SONRRare described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule. 2. The compound of claim 1 , wherein the active agent is an androgen.3. The compound of claim 1 , wherein the active agent is testosterone.4. The compound of claim 1 , wherein the active agent is 7α claim 1 ,11β-dimethyl-estra-4 claim 1 ,9-dien-17β-ol5. The compound of claim 1 , wherein the active agent is an estrogen.6. The compound of claim 1 , wherein the active agent is estradiol.7. The compound of claim 1 , wherein the active agent is estriol.8. The compound of claim 1 , wherein the active agent is a progestin.9. The compound of claim 1 , wherein the active ingredient is trimesgestone.10. The compound of claim 1 , wherein Rand Rare linked together to form a cycloalkyl or a 3-7 membered ring with up to one heteroatom.11. The compound of claim 10 , wherein n is 1; m is 0; L is 1; hAr is aryl; Rand Rare H claim 10 , and Y and X are H.12. The compound of claim 10 , wherein n is 1; m is 1; L is 0; hAr is aryl; Rand Rare H claim 10 , and Y and X are H.13. The compound of claim 1 , wherein Ris alkyl.14. The compound of claim 13 , wherein n is 1; Ris H; m is 0; L is 1; hAr is aryl; Y and X are H; and Rand Rare H.15. The compound of claim 13 , wherein Ris isopropyl.14. The compound of claim 13 , wherein Ris methyl.15. A pharmaceutical composition comprising a compound as described in and one or more pharmaceutically acceptable carriers.17. The compound of claim 16 , wherein the active agent is an androgen.18. The compound of claim 16 , wherein the active agent is testosterone.19. The compound of claim 16 , wherein the active agent is 7α claim 16 ,11β-dimethyl-estra-4 claim 16 ,9-dien-17β-ol20. The compound of claim 16 , wherein the active agent is an estrogen.21. The compound of claim 16 , wherein the active agent is estradiol.22. The compound of ...

THERMAL ANALYSIS OF SEMICONDUCTOR DEVICES

A method for determining a thermal impedance of a sample device is described. According to the method, a sample device is heated to an initial temperature. A pulsed power including a sequence of pulses is applied to the sample device. Temperature of the sample device is measured in a time-dependent manner. A thermal impedance of the sample device is determined based on the temperature of the sample device and the pulsed power. 1. A method for determining a thermal impedance of a sample device , comprising:heating a sample device to an initial temperature;applying a pulsed power to the sample device, the pulsed power including a sequence of pulses;measuring a temperature of the sample device in a time-dependent manner; anddetermining a thermal impedance of the sample device based on the temperature of the sample device and the pulsed power.2. The method according to claim 1 ,wherein pulses of the sequence of pulses alternate between a first amplitude and a second amplitude.3. The method according to claim 2 , further comprising:heating the sample device to the initial temperature by applying a heating power to the sample device,wherein the first amplitude and the second amplitude are different from each other;wherein the first amplitude and the second amplitude differ from the heating power by a same amplitude difference.4. The method according to claim 1 ,wherein the step of applying the pulsed power to the sample device is performed for a first total duration;wherein pulses of the sequence of pulses have pulse duration of integral multiples of a given shortest pulse duration;wherein the method further comprises:applying another pulsed power to the sample device for a second total duration, the second pulsed power including pulses having pulse durations of a different shortest pulse duration.5. The method according to claim 1 , further comprising:after the step of applying the pulsed power, applying a sensing power equal to or below a minimum of the pulsed power.6. ...

Novel coating system (ii)

The present patent application relates to a novel coating system for coating solid particles, which comprise PUFAs (and/or salts thereof), wherein the coating comprises at least one protein hydrolysate. Furthermore it relates to compositions coated with such a coating system and the use of such compositions in the production of food, feed, dietary supplements and/or pharmaceutical products.

BEVERAGES COMPRISING STABLE GRANULES OF MILLED LUTEIN

Beverages are provided which include a beverage liquid and granules mixed with the beverage liquid The granules include: 1. A beverage comprising a beverage liquid and granules mixed with the beverage liquid , wherein the granules comprise: D [3,2] in the range of from 0.6 to 1.5 μm, and', 'D [v, 0.5] in the range of from 1.1 to 3.5 μm,, '(i) a milled carotenoid consisting of lutein and/or zeaxanthin, wherein the milled carotenoid has the following particle size distribution(ii) a matrix material which encapsulates the milled carotenoid and comprises at least one modified food starch, a glucose syrup and sucrose, and(iii) a water-soluble antioxidant, wherein D [3,2] in the range of from 200 to 300 μm, and', 'D [v, 0.5] in the range of from 220 to 320 μm, and wherein, 'the granules have the following particle size distributionall D values are as measured by laser diffraction according to the Fraunhofer scattering model, and whereinthe granules do not include an oil or a gelatin.2. The beverage according to claim 1 , wherein the beverage is a soft drink having a pH in the range of from 2 to 5.3. The beverage according to claim 1 , wherein the beverage has a color stability DE* 1 for 60 days.4. The beverage according to claim 1 , wherein the beverage has a turbidity 150 NTU.5. The beverage according to claim 1 , wherein the amount of the milled carotenoid claim 1 , the amount of the modified food starch claim 1 , the amount of the glucose syrup claim 1 , the amount of sucrose and the amount of the water-soluble antioxidant are together at least 90 wt. % of the total weight of the granules.6. The beverage according to claim 1 , wherein the amount of the milled carotenoid claim 1 , the amount of the modified food starch claim 1 , the amount of the glucose syrup claim 1 , the amount of sucrose and the amount of the water-soluble antioxidant are together at least 95 wt. % of the total weight of the granules.7. The beverage according to claim 1 , wherein the amount of ...

NOVEL COATING SYSTEM (I)

The present patent application relates to a novel coating system for coating solid particles, which comprise PUFAs (and/or salts thereof), wherein the coating comprises at least one cyclodextrin. Furthermore it relates to compositions coated with such a coating system and the use of such compositions in the production of food, feed, dietary supplements and/or pharmaceutical products. 1. A coating system comprisingat least 10 wt-%, based on the total weight of the coating system, of cyclodextrin.2. A coated composition comprising(a) a core, which is a sold formulation comprises at least one PUFA (and/or salts thereof) and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(b) a coating system according to .'}3. The coated composition according to claim 2 , comprising(a) 70 to 99.5 wt-%, based on the total weight of the composition, of core and(b) 0.5 to 30 wt-%, based on the total weight of the composition, of coating system.4. Process of production of a coated composition according claim 2 , wherein(i) the cores (which comprise PUFA (and/or salts thereof)) are produced by beadlet process, spray drying or spray-granulation in a first step;(ii) these cores (solid particles) are coating in a second step by a solution, dispersion or slurry of the coating material (cyclodextrin), and(iii) afterwards the coated particles are dried.5. Use of the coated particles according to in food products claim 2 , feed products claim 2 , dietary supplements and/or pharmaceutical products.6. Food products claim 2 , feed products claim 2 , dietary supplements and/or pharmaceutical products claim 2 , comprising at least one coated composition according to . The present patent application relates to a novel coating system for coating solid particles, which comprise PUFAs (and/or salts thereof), wherein the coating comprises at least one cyclodextrin. Furthermore it relates to compositions coated with such a coating system and the use of such compositions in the production of food, feed, ...

PUFA SALT FORMULATIONS (II)

The present patent application relates to novel polyunsaturated fatty acid salt (PUFA salts) solid formulations. 1. A solid formulation comprising(i) at least one PUFA salt, and(ii) at least one protein hydrolysate from a starch containing plant.2. Solid formulation according to claim 1 ,wherein the average particle size (Dv50) of the solid formulation is 10-200 μm.3. Solid formulation according to claim 1 ,wherein the average particle size (Dv50) of the solid formulation is 200-1000 μm.4. Solid formulation according to claim 1 ,wherein the average particle size (Dv50) of the solid formulation is more than 1000 μm.5. Solid formulation according to claim 1 , wherein the PUFA salts are the sodium claim 1 , potassium claim 1 , magnesium and/or calcium salts.6. Solid formulation according to claim 1 , wherein the PUFA salts are chosen from the group consisting of linoleic acid claim 1 , arachidonic acid claim 1 , γ-linolenic acid claim 1 , dihomo-γ-linolenic acid claim 1 , α-linolenic acid claim 1 , eicosapentaenoic acid claim 1 , and docosahexaenoic acid in form of its sodium claim 1 , potassium and/or calcium salts.7. Solid formulation according to claim 1 , wherein the solid formulation comprises 5-80 wt-% claim 1 , based on the total weight of the solid formulation claim 1 , of at least one PUFA salt.8. Solid formulation according to claim 1 , wherein the solid formulation comprising 10-75 wt-% claim 1 , based on the total weight of the solid formulation claim 1 , of at least one protein hydrolysate from a starch containing plant.9. Solid formulation according to claim 1 , wherein the solid formulation comprises up to 30 wt-% claim 1 , based on the total weight of the solid formulation claim 1 , of at least one gum.10. Solid formulation according to claim 1 , wherein the solid formulation comprises up to 30 wt-% claim 1 , based on the total weight of the solid formulation claim 1 , of at least one sugar alcohol.11. Solid formulation according to claim 1 , wherein ...

PUFA SALT FORMULATIONS (I)

The present patent application relates to novel polyunsaturated fatty acid salt (PUFA salts) solid formulations. 1. A solid formulation comprising(i) at least one PUFA salt, and(ii) a casein phosphopeptide.2. Solid formulation according to claim 1 ,wherein the average particle size (Dv50) of the solid formulation is 10-200 μm.3. Solid formulation according to claim 1 ,wherein the average particle size (Dv50) of the solid formulation is 200-1000 μm.4. Solid formulation according to claim 1 ,wherein the average particle size (Dv50) of the solid formulation is more than 1000 μm.5. Solid formulation according to claim 1 , wherein the PUFA salts are the sodium claim 1 , potassium claim 1 , magnesium and/or calcium salts.6. Solid formulation according to claim 1 , wherein the PUFA salts are chosen from the group consisting of linoleic acid claim 1 , arachidonic acid claim 1 , γ-linolenic acid claim 1 , dihomo-γ-linolenic acid claim 1 , α-linolenic acid claim 1 , eicosapentaenoic acid claim 1 , and docosahexaenoic acid in form of its sodium claim 1 , potassium and/or calcium salts.7. Solid formulation according to claim 1 , wherein the solid formulation comprises 5-80 wt-% claim 1 , based on the total weight of the solid formulation claim 1 , of at least one PUFA salt.8. Solid formulation according to claim 1 , wherein the solid formulation comprising 10-75 wt-% claim 1 , based on the total weight of the solid formulation claim 1 , of casein phosphopeptide.9. Solid formulation according to claim 1 , wherein the solid formulation comprises up to 30 wt-% claim 1 , based on the total weight of the solid formulation claim 1 , of at least one gum.10. Solid formulation according to claim 1 , wherein the solid formulation comprises up to 30 wt-% claim 1 , based on the total weight of the solid formulation claim 1 , of at least one sugar alcohol.11. Solid formulation according to claim 1 , wherein the solid formulation comprises at least one auxiliary agent claim 1 , wherein the ...

Beverages comprising stable granules of milled lutein

The present invention is directed towards the use of granules in beverages, wherein the granules comprise (i) a milled carotenoid selected from the group consisting of lutein and zeaxanthin and any mixture thereof having the following particle size distribution: D [3,2] in the range of from 0.6 to 1.5 μm, and D [v, 0.5] in the range of from 1.1 to 3.5 μm, and (ii) a matrix comprising at least one modified food starch, a glucose syrup and sucrose, (iii) a water-soluble antioxidant, wherein the granules have the following particle size distribution: D [3,2] in the range of from 200 to 300 μm, and D [v, 0.5] in the range of from 220 to 320 μm, all D values as measured by laser diffraction according to the Fraunhofer scattering model, whereby the milled carotenoid is encapsulated by the matrix. The present invention is also directed towards the beverages and the granules as such, as well as to a process for the manufacture of the granules. Preferably the carotenoid is lutein, zeaxanthin or any mixture thereof.

New tablettable formulation of lutein and/or zeaxanthin

The present invention is directed towards a solid formulation comprising a milled carotenoid, at least one hydrocolloid, a glucose syrup, sucrose and at least one water-soluble antioxidant (preferably sodium ascorbate), wherein the carotenoid is selected from the group consisting of lutein and zeaxanthin and any mixture thereof, wherein the hydrocolloid is selected from the group consisting of modified food starches and any mixtures thereof, and wherein the milled carotenoid has the following particle size distribution: D [3, 2] in the range of from 0.6 to 1.5 μm and D [v, 0.5] in the range of from 1.1 to 3.5 μm, all D values as measured by laser diffraction (Malvern Instruments Ltd, Malvern, UK, Mastersizer 3000) according to the Fraunhofer scattering model. This solid formulation is in form of granules which are used for dietary supplements and pharmaceuticals, such as e.g. multi-vitamin and/or multi-mineral tablets. Surprisingly these tablets show a low compression loss.

Shifting mechanism for a drill press

A transmission for a power tool includes an intermediate shaft and first and second driving gears coupled for co-rotation with the intermediate shaft. The transmission also includes an output shaft having first and second driven gears continuously engaged with the respective first and second driving gears. The transmission further includes a hub coupled for co-rotation with the output shaft, and a collar. The collar is axially movable along the output shaft between a first position in which the collar couples the first driven gear to the hub for co-rotation with the output shaft, and a second position in which the collar couples the second driven gear to the hub for co-rotation with the output shaft.

Biological Nutrient Removal Process Control System

A process for biological nutrient removal including: receiving fluid having sludge in a basin through a sludge inlet; activating an aeration system based at least partially on a time of day; periodically measuring a potassium level of the fluid; determining a potassium rate of change based on the periodic measurements of potassium level; and deactivating the aeration system based at least partially on the determined potassium rate of change. A system for biological nutrient removal is also disclosed.

NEW FORMULATION

The present invention relates to a new formulation of specific nutritional ingredients (nutraceuticals) and/or pharmaceutical compounds. 1. A multiple unit pellet system , which comprises at least two different pellets(a) pellets (pellets (a)) comprising riboflavin and(b) particles (particles (b)) comprising at least one aminosalicylate and/or at least a pharmaceutically acceptable salt and/or at least one prodrugs thereof,wherein the pellets (a) are coated.2. Multiple unit pellet system according to claim 1 , which is in the form of a tablet.3. Multiple unit pellet system according to claim 1 , which comprises at least one auxiliary ingredient.4. Multiple unit pellet system according to claim 3 , wherein the at least one auxiliary ingredient is chosen from the group consisting of binders claim 3 , fillers claim 3 , lubricants claim 3 , proteins claim 3 , dyes claim 3 , flavours claim 3 , sweeteners claim 3 , minerals claim 3 , and antioxidants without being limited thereto5. Multiple unit pellet system according to claim 3 , wherein the total amount of the auxiliary ingredients is up to 99 wt-% claim 3 , based on the total weight of the MUPS tablet.6. Multiple unit pellet system according to claim 1 , wherein the at least one aminosalicylate and/or at least a pharmaceutically acceptable salt and/or at least one prodrugs thereof is chosen from the group consisting of aminosalicylates consists of 4-aminosalicylic acid claim 1 , Balsalazide claim 1 , Olsalazine claim 1 , Sulfasalazine and Mesalazine (5-Aminosalicylic acid).7. Multiple unit pellet system according to claim 1 , wherein the coating material is chosen from the group consisting of cellulose acetate phthalate (CAP) (Aquateric®) claim 1 , poly vinyl acetate phthalate (PVAP) (Coateric®) claim 1 , hydroxypropyl methyl cellulose phthalate (HPMCP) claim 1 , and methacrylic acid copolymers claim 1 , shellac claim 1 , fats alginate claim 1 , chitosan claim 1 , pectin claim 1 , cyclodextrin and other gums.8. ...

EXTRUSION PROCESS

The present invention relates to a process for the production of extruded formulations comprising oil-in-water emulsion droplets, to such formulations as well as to the use. 1. Process of production of an extrudate , wherein that extrudate comprises oil-in-water emulsion droplets and wherein these oil-in-water emulsion droplets comprise at least one fat soluble compound and at least one emulsifier and water , characterised in that the emulsifying process is carried out in the extruder.2. Process according to claim 1 , wherein the fat soluble compounds are oils or vitamins.3Plukenetia volubilis. Process according to claim 1 , wherein fat soluble compound is chosen from the group consisting of coconut oil claim 1 , corn oil claim 1 , cottonseed oil claim 1 , olive oil claim 1 , palm oil claim 1 , peanut oil claim 1 , rapeseed oil claim 1 , canola oil claim 1 , safflower oil claim 1 , sesame oil claim 1 , soybean oil claim 1 , sunflower oil claim 1 , hazelnut oil claim 1 , almond oil claim 1 , cashew oil claim 1 , macadamia oil claim 1 , mongongo nut oil claim 1 , pracaxi oil claim 1 , pecan oil claim 1 , pine nut oil claim 1 , pistachio oil claim 1 , sacha Inchi () oil claim 1 , walnut oil claim 1 , polyunsaturated fatty acids (such as triglyceride and/or ethyl ester claim 1 , (for example arachidonic acid claim 1 , eicosapentaenoic acid claim 1 , docosahexaenoic acid and -linolenic acid and/or ethyl ester) claim 1 , oily nutraceuticals (such as rosemary extract claim 1 , oregano extract claim 1 , hop extract claim 1 , and other lipophilic plant extracts) claim 1 , vitamin A or its esters (for example vitamin A acetate and vitamin A palmitate) claim 1 , vitamin E or its esters (for example vitamin E acetate) claim 1 , vitamin K (phytomenadione) and vitamin D3 (cholecalciferol).4. Process according to claim 1 , wherein the fat soluble compound is chosen from the group consisting of corn oil claim 1 , vitamin A or its esters (for example vitamin A acetate and vitamin A ...

New delivery system

The present invention relates to a new delivery system for nutritional ingredients (nutraceuticals). These nutritional ingredients are useful for gut and metabolic health in monogastric animals, especially in humans.

COMBINATION OF ESTROGENS PLUS ANTIPROGESTINS WITH SIGNIFICANT PARTIAL AGONISTIC EFFECT AS AN EFFECTIVE TREATMENT OF MENOPAUSAL SYMPTOMS AND FOR PREVENTION OF THE OCCURRENCE OF BREAST CANCER

Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy. 6. A pharmaceutical composition comprising an estrogen and a partial agonistic antiprogestin.7. The pharmaceutical composition of claim 6 , wherein the partial agonistic antiprogestin has an EC 50 between 1 nM to 10 nM in a progesterone transactivation assay claim 6 , carried out on human breast cancer (T47D) cells claim 6 , for agonistic activity.8. The pharmaceutical composition of claim 6 , wherein the partial agonistic antiprogestin has an EC 50 of between 0.1 nM and 5 nM in a progesterone transactivation assay claim 6 , carried out on human breast cancer (T47D) cells claim 6 , for antagonistic activity.9. The pharmaceutical composition of claim 6 , wherein the partial agonistic antiprogestin has an EC 50 between 1 nM to 10 nM in a progesterone transactivation assay claim 6 , carried out on human breast cancer (T47D) cells claim 6 , for agonistic activity; and wherein the partial agonistic antiprogestin has an EC 50 of between 0.1 nM and 5 nM in a progesterone transactivation assay claim 6 , carried out on human breast cancer (T47D) cells claim 6 , for antagonistic activity.10. The pharmaceutical composition of claim 6 , wherein the partial agonistic antiprogestin shows a ratio of the EC 50 values between agonistic and antagonistic activity in a progesterone transactivation assay claim 6 , carried out on human breast cancer (T47D) cells claim 6 , of between 1:0.5 to 1:10.11. The pharmaceutical composition of claim 6 , wherein the partial agonistic antiprogestin is classified as a pure mesoprogestin in the Guinea pig model.12. The pharmaceutical composition of claim 6 ...

Semiconductor Package

A semiconductor package (″), the package (″) comprising a first substrate () comprising at a front cavity side (′) a plurality of cavities (′), each of the cavities (′) having a bottom wall () and side walls (), and having a conductive path () forming an electric contact surface () located at the inner side of the bottom wall () of the cavity (′), a plurality of semiconductor elements (), each of the semiconductor elements () comprising a first electric contact surface () on a first side () and a second electric contact surface () on a second side () opposite to the first side (), wherein at least one of the semiconductor elements () is placed within a corresponding cavity (′) at the front cavity side (′) of the first substrate (), wherein the first electric contact () of the semiconductor element () and the electric contact surface () at the inner side of the bottom wall () of the corresponding cavity (′) are electrically conductive bonded in a material-locking manner, and a second substrate (), the second substrate () being attached with a connection side () to the front cavity side (′) of the first substrate () thereby encapsulating the semiconductor elements () located within the corresponding cavities (′) at the front cavity side (′) of the first substrate (). 1. A semiconductor package , the package comprising:a first substrate comprising, at a front cavity side, a plurality of cavities, each of the cavities having a bottom wall and side walls, and having a conductive path forming an electric contact surface located at the inner side of the bottom wall of the cavity,a plurality of semiconductor elements, each of the semiconductor elements comprising a first electric contact surface on a first side and a second electric contact surface on a second side opposite to the first side, wherein at least one of the semiconductor elements is placed within a corresponding cavity at the front cavity side of the first substrate, wherein the first electric contact of the ...

Cover assemblies for mattresses

A cover assembly for a mattress is provided that includes a first cover and a second cover. The first cover includes a top panel, a bottom panel, and a continuous side panel collectively defining a cavity for enclosing the mattress. The second cover includes a top surface and a bottom surface, with the second cover being positioned over and dimensionally-sized to cover at least the top panel of the first cover. A fastener then connects the second cover to the first cover along the perimeter of the second cover. Methods for marking a mattress are also provided that include the step of marking an indicia indicative of a characteristic of a mattress on the top surface of the second cover of the cover assembly.

PRODUCTION OF BEADLETS COMPRISING PROBIOTIC COMPOUNDS

The present invention relates a process of production of beadlets comprising probiotic compounds in a matrix comprising at least one starch and/or starch derivative, to such beadlets and to the use of such specific beadlets in food (for humans and animals) as well as in premixes. 1. A process for preparing beadlets containing a high content of at least one probiotic , wherein the process comprises the steps of: (i) at least one probiotic in an amount of 40 wt. %-85 wt. %, based on the total weight of the beadlets, and', '(ii) at least one starch and/or starch derivative, and thereafter, '(a) forming an aqueous probiotic-containing solution consisting of(b) converting the aqueous probiotic-containing solution into a dry powder by spray drying the solution into a fluidized bed of a collecting powder to form beadlets comprising the at least one probiotic, wherein (b1) dehumidifying hot atomizing air to a water content of less than about 3 g/kg to obtain hot dehumidified atomizing air;', '(b2) atomizing the aqueous probiotic-containing solution into a spray zone of a spraying tower at a solution temperature of from about 15° C. to about 80° C. with the hot dehumidified atomizing air at a temperature sufficient to provide a spray zone temperature of about 60° C. to about 120° C.; while', '(b3) fluidizing the fluidized bed of powder within a bottom of the spraying tower with cold fluidizing air at a temperature of between 5° C. to 20° C. at a ratio of hot atomizing air flow to cold fluidizing air flow in a range of 1:8 to 1:4 to achieve a temperature of the fluidized bed of powder of between about 5° C. to 20° C.,', '(b4) controlling the temperature of the fluidized bed by controlling the supply and temperature of the cold fluidizing air, and', '(b5) covering the beadlets by a powder coating layer comprised of at least one coating material selected from the group consisting of starches, calcium silicate, calcium aluminum silicate and tri-calcium phosphate so that the ...

FAST RELEASE BENZOIC ACID IN FEED

The present invention relates to the use of benzoic acid prills in the feed industry. Despite of having a reduced surface area/volume ratio, the benzoic acid prills as used in the context of the present invention release benzoic acid faster than benzoic acid flakes. Compositions comprising such prills are useful for balancing the microflora in an animal's gastro-intestinal system, for acidification of feed and/or urine, and/or for reducing digestive disorders of an animal. 1. Method of producing benzoic acid prills , said method comprising the steps:(i) providing particles by spray cooling molten benzoic acid;(ii) removing non-spherical particles from the particles provided in step (i).2. Method according to claim 1 , wherein step (i) is done by spraying molten benzoic acid into a gaseous cooling medium claim 1 , and wherein said gaseous cooling medium is preferably air.3. Method according to claim 1 , wherein in step (ii) claim 1 , the difference between the sliding friction of non-spherical particles and the rolling friction of spherical particles is used for separating non-spherical particles from spherical particles.4. Animal food comprising benzoic acid prills.5. Animal food according to claim 4 , wherein said animal food is a feed additive claim 4 , a premix or feed.6. Animal food according to claim 4 , said animal food further comprising at least one essential oil claim 4 , wherein said essential oil is preferably thymol and/or eugenol.7. Process for the preparation of animal food claim 4 , said process comprising the step of adding benzoic acid prills to a composition which can be fed to an animal.8. Process according to claim 7 , wherein said animal food is a feed additive claim 7 , a premix or feed.9. Use of benzoic acid prills for acidification of feed and/or urine.10. Use according to claim 9 , wherein the urine of an animal is acidified by feeding benzoic acid prills to the animal claim 9 , and wherein said animal is preferably a domestic animal claim 9 ...

BEADLETS COMPRISING HOP ACID SALTS IN A STARCH MATRIX

The present invention relates to a process for production of beadlets comprising hop acids salts in a matrix comprising at least one starch and/or starch derivative, to such beadlets and to the use of such specific beadlets. 1. Process for preparing beadlets , which comprise at least one hop acid salt , comprising: (i) at least a hop acid salt and', '(ii) at least one starch and/or starch derivative,, '(a) forming an aqueous solution of'}(b) adjusting the pH of the solution to pH greater than 9(c) converting the solution into a dry powder by spray drying into a starch collecting powder.2. A process according to wherein the hop acid salt is a mixture primarily comprising lupulone claim 1 , colupulone claim 1 , and adlupulone salts.3. A process according to wherein the hop acid salt is a potassium salt.4. A process according to wherein the starch and/or starch derivatives are chosen from the group consisting of amylopectin claim 1 , maltodextrins claim 1 , yellow dextrins and pregelatinised starches.5. A process according to wherein the starch and/or starch derivatives are maltodextrins and at least one further starch and/or at least one further starch derivative as defined in .6. A process according to claim 1 , wherein the beadlets are covered by a powder coating.7. A process according to claim 1 , wherein the beadlets comprise 5 to 25 wt-% claim 1 , based on the total weight of the beadlets claim 1 , of at least one hop acid salt.8. A process according to claim 1 , wherein the beadlets comprise at least 30 wt-% claim 1 , preferably at least 50 wt-% claim 1 , based on the total weight of the beadlets claim 1 , of at least one starch and/or at least one starch derivative and of the starch powder coating layer.9. A process according to claim 1 , wherein the beadlets compriseat least 3 wt-%, based on the total weight of the beadlets, of starch powder coating layer.10. Beadlets comprising(i) 10 wt-% to 15 wt-%, based on the total weight of the beadlets, of at least one ...

Imidazolyl progesterone antagonists

Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.

BEADLETS COMPRISING HOP ACID SALTS IN A PROTEIN MATRIX

The present invention relates a process of production of beadlets comprising at least one hop acid salt in a matrix comprising at least one protein, to such beadlets and to the use of such specific beadlets in feed as well as in feed premixes. 1. Process for preparing beadlets , which comprise at least one hop acid salt , comprising: (i) at least a hop acid salt and', '(ii) at least one protein or protein mixture,, '(a) forming an aqueous solution of'}(b) adjusting the pH of the solution to pH greater than 9(c) converting the solution into a dry powder by spray drying into a collecting powder.2. A process according to claim 1 , wherein the hop acid salt is a mixture primarily comprising lupulone claim 1 , colupulone claim 1 , and adlupulone salts.3. A process according to wherein the hop acid salt is a potassium salt.4. A process according to claim 1 , wherein the proteins are chosen from a plant source such as peas claim 1 , soya claim 1 , castor beans claim 1 , cotton claim 1 , lupins claim 1 , potatoes claim 1 , sweet potatoes claim 1 , manioc claim 1 , rapeseed claim 1 , sunflowers claim 1 , sesame claim 1 , linseed claim 1 , safflower claim 1 , lentils claim 1 , nuts claim 1 , wheat claim 1 , rice claim 1 , maize claim 1 , barley claim 1 , rye claim 1 , oats and sorghum claim 1 , an animal source such as blood claim 1 , bones claim 1 , skin claim 1 , milk and eggs or a microbial source such as bacteria and yeasts.5. A process according to wherein the proteins are chosen from the group consisting of gelatines claim 4 , hydrolysed gelatines and milk proteins such as whey protein or casein.6. A process according to claim 1 , wherein the beadlets are covered by a powder coating.7. A process according to claim 1 , wherein the beadlets comprise 10 wt.-% to 15 wt-% claim 1 , based on the total weight of the beadlets claim 1 , of at least one hop acid salt.8. A process according to claim 1 , wherein the beadlets comprise at least 30 wt-% claim 1 , preferably at least ...

COATED PARTICLES

The present patent application relates to novel red-orange coated particles, which are mainly used in (dry) formulations for instant beverages. The advantage of these coated particles is that they are red to orange as such (also in the formulations for instant beverages, wherein they can be identified by the naked eye as individual discrete coloured particles), but upon dissolution of the instant beverage powder these particles will dissolve as well and will not interfere with or change the intended color of the ready-to drink instant beverages made from the instant beverage dry powders.

Couponless rewards in response to a transaction

A system and method provide rewards or loyalty incentives to card member customers. The system includes an enrolled card member customer database, an enrolled merchant database, a participating merchant offer database and a registered card processor. The enrolled card member customer database includes transaction accounts of card member customers enrolled in a loyalty incentive program. The enrolled merchant database includes a list of merchants participating in the loyalty incentive program. The participating merchant offer database includes loyalty incentive offers from participating merchants. The registered card processor receives a record for charge for a purchase made with an enrolled merchant by an enrolled card member customer and uses the record of charge to determine whether the purchase qualifies for a rebate credit in accordance with a discount offer from the enrolled merchant. If the purchase qualifies for a rebate credit, the registered card processor provides the rebate credit to an account of the enrolled card member customer. The system provides a coupon-less way for merchants to provide incentive discounts to enrolled customers.

TARGETED DELIVERY OF PROGESTINS AND ESTROGENS VIA VAGINAL RING DEVICES FOR FERTILITY CONTROL AND HRT PRODUCTS

A variety of different intravaginal drug delivery devices are described for the delivery of estrogens and progestins. The release rate of estrogens and progestins can be controlled by varying the matrix material or by the application of a thin coating. The intravaginal drug delivery devices may be composed of one or more individual compartments. By controlling various physical and chemical parameters, non-zero release rates of the estrogen or progestins may be achieved.

HORMONAL CONTRACEPTION USING A VAGINAL RING WHICH RELEASES ESTRIOL

A variety of different intravaginal drug delivery devices are described for the delivery of estrogens and progestins. The release rate of estrogens and progestins can be controlled by varying the matrix material or by the application of a thin coating. The intravaginal drug delivery devices may be composed of one or more individual compartments. By controlling various physical and chemical parameters, non-zero release rates of the estrogen or progestins may be achieved.

PRO-DRUG FORMING COMPOUNDS

Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SONRRare described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule. 140-. (canceled)43. The compound of claim 41 , wherein the active agent is testosterone.44. The compound of claim 41 , wherein the active agent is 7α claim 41 , 11β-dimethyl-estra-4 claim 41 , 9-dien-17β-ol.45. The compound of claim 41 , wherein the active agent is estradiol.46. The compound of claim 41 , wherein the active agent is estriol.47. The compound of claim 41 , wherein the active ingredient is trimesgestone.48. The compound of claim 41 , wherein Ris alkyl.49. The compound of claim 41 , wherein Ris H; Y and X are H; and Rand Rare H.50. The compound of claim 41 , wherein Ris isopropyl.51. The compound of claim 41 , wherein Ris methyl.52. The compound of claim 41 , wherein hAr is thiophene claim 41 , pyridine claim 41 , isoxazole claim 41 , phthalimide claim 41 , pyrazole claim 41 , indole claim 41 , or furan.53. The compound of claim 41 , wherein hAr is pyridine or furan.55. A pharmaceutical composition comprising a compound as described in and one or more pharmaceutically acceptable carriers.58. The compound of claim 56 , wherein Ar is naphthyl claim 56 , biphenyl claim 56 , diphenylmethyl claim 56 , or 2 claim 56 ,2-diphenyl-1-ethyl. The present application is a continuation of U.S. patent application Ser. No. 14/329,322, filed Jul. 11, 2014, which claims priority to U.S. Provisional Application Ser. No. 61/844,985 entitled “Pro-Drug Forming Compounds” filed Jul. 11, 2013, both of which are incorporated herein by reference in its entirety.The invention generally relates to derivatives of biologically active molecules which show a higher oral bioavailability and therefore higher biological activity than the original biologically active drug.Many endogenic substances, natural products and synthetic substances with therapeutically useful ...

Node seat to base mounting assembly

A seating unit for use in a space including a supporting floor surface, the seating unit comprising a seat structure comprising a mounting bracket having a female connector, a tablet assembly comprising a support arm having a mounting collar on an end and a base having a lower end to be supported by the floor surface and including a base mounting assembly and wherein the base mounting assembly comprises a cup attached to the base, a base tube having a first end inserted into the cup and a second end extending through the mounting collar and mateably engaging the female connector.

NEW DELIVERY SYSTEM

The present invention relates to a new delivery system for nutritional ingredients (nutraceuticals). These nutritional ingredients are useful for gut and metabolic health in monogastric animals, especially in humans. 1. Delivery system consisting of(a) a solid core, which comprises at least one water-soluble vitamin, and(b) an inner coating comprising at least one fermentable biopolymer, which is crosslinked, and(c) an outer coating which is resistant to stomach conditions and releasing in the small intestine.2. Delivery system according to claim 1 , wherein the solid core comprises vitamin B2.3. Delivery system according to claim 1 , wherein the material of the inner coating is chosen from group consisting of alginate claim 1 , chitosan claim 1 , pectin claim 1 , cyclodextrin as well as other gums.4. Delivery system according to claim 1 , wherein the inner coating layer is crosslinked with Mg and/or Ca ions.5. Delivery system according to claim 1 , wherein the outer coating is chosen from group consisting of shellac claim 1 , methacrylate copolymers and fats.6. Process of production delivery systems according to claim 1 , wherein the process is carried out batchwise.7. Process of production delivery systems according to claim 1 , wherein the process is carried out continuously.8. Process for the production of a premix claim 1 , dietary supplement claim 1 , food product claim 1 , feed product claim 1 , personal care product or pharmaceutical product using at least one delivery systems according to .9. Premix claim 1 , dietary supplement claim 1 , food product claim 1 , feed product claim 1 , personal care product or pharmaceutical product comprising at least one delivery systems according to . The present invention relates to a new delivery system of water-soluble vitamins (i.e. B vitamins (especially B2)) for the large intestine. These nutritional ingredients are useful for gut and metabolic health in monogastric animals (such as swine and poultry as well as fish), ...

Brushless motor for a power tool

A power tool including a housing, a controller within the housing, and a brushless motor within the housing and controlled by the controller. The brushless motor including a stator assembly including a stator core having stator laminations with an annular portion and inwardly extending stator teeth. The stator assembly defines a stator envelope in an axial direction extending between axial ends of stator end caps of the stator assembly. The brushless motor further includes a rotor assembly including a rotor core having rotor laminations and defining a central aperture that extends in the axial direction and that receives a shaft, and a position sensor board assembly including position sensors and configured to provide position information of the rotor core to the controller. The rotor assembly and the position sensor board assembly are provided at least partially within the stator envelope.

HORMONAL CONTRACEPTION USING A VAGINAL RING WHICH RELEASES ESTRIOL AND TRIMEGESTONE

The invention relates to an intravaginal drug delivery device for hormonal contraception with prevention/reduction of intermenstrual bleeding and menopausal cycle disorders. The intravaginal drug delivery device includes estriol or a precursor of this compound and a progestogen or a precursor thereof. 1. An intravaginal drug delivery device comprising estriol in combination with a progestin or a precursor thereof; wherein the intravaginal drug delivery device releases estriol and the progestin , over a period of at least 21 days , in an amount sufficient to:(a) produce a contraceptive state in a female subject; and(b) inhibit or prevent menstrual bleeding during and after use of the intravaginal drug delivery device.2. The device of claim 1 , wherein the device is composed of two or more compartments claim 1 , wherein one of the two or more compartments comprises estriol and a separate one of the two or more compartments comprises the progestin.3. The device of claim 2 , wherein the compartment comprising estriol is an uncoated compartment comprising estriol in a matrix comprising ethylene vinyl acetate.4. The device of claim 3 , wherein the matrix comprises ethylene vinyl acetate having a high vinyl acetate content.5. The device of claim 2 , wherein the compartment comprising the progestin is a coated compartment comprising the progestin in a core matrix comprising ethylene vinyl acetate and a skin layer comprising ethylene vinyl acetate substantially devoid of any estrogens or progestins.6. The device of claim 5 , wherein the core matrix comprises ethylene vinyl acetate having a high vinyl acetate content and wherein the skin comprises ethylene vinyl acetate having a low vinyl acetate content.7. The device of claim 2 , wherein the two or more compartments are in the form of a cylinder claim 2 , and wherein the cylindrical compartments are joined together to form a ring.8. The device of claim 1 , wherein the device releases estriol in doses between 0.05 and 1.0 mg/ ...

PROCESS FOR PRODUCING COATED PARTICLES

The present patent application relates to coated particles. These coated particles show improved properties when used in compressed tablets. 2. Process according to claim 1 , wherein the cores are introduced into the top spraying device at room temperature.3. Process according to claim 1 , wherein the inlet temperature kept at a constant temperature.4. Process according to claim 3 , wherein the inlet temperature kept at a constant temperature of 30-60° C.5. Process according to claim 1 , wherein the spraying rate for the molten coating layer compound is kept constant.6. Process according to claim 5 , wherein the spraying rate is 2 g·minup to 8 g·min.7. Process according to claim 1 , wherein an atomizing air pressure of 1 bar and an atomizing air temperature of 100 to 120° C. is used for the entire process.8. Process according to claim 1 , wherein the coating system of the coated particles comprises at least one wax and/or at least one fat claim 1 , which has a dropping point of from 30 to 85° C. claim 1 , preferably 40 to 70° C.9. Process according to claim 1 , wherein the coating system of the coated particles comprises at least one wax and/or at least one fat chosen from the group consisting of glycerine monostearate claim 1 , carnauba wax claim 1 , candelilla wax claim 1 , sugarcane wax claim 1 , palmitic acid claim 1 , stearic acid claim 1 , (fully) hydrogenated cottonseed oil claim 1 , (fully) hydrogenated palm oil and (fully) hydrogenated rapeseed oil.10. Process according to claim 9 , wherein the coating system of the coated particles comprises at least one wax and/or at least one fat chosen from the group consisting of carnauba wax claim 9 , candelilla wax claim 9 , sugarcane wax and (fully) hydrogenated palm oil.11. Process according to claim 1 , wherein the coating system of the coated particles comprises 50 wt-%-90 wt-% claim 1 , based on the total weight of the coated particles claim 1 , of a core and 10 wt-%-50 wt-% claim 1 , based on the total weight ...

Brushless motor for a power tool

A power tool including a housing, a controller within the housing, and a brushless motor within the housing and controlled by the controller. The brushless motor including a stator assembly including a stator core having stator laminations with an annular portion and inwardly extending stator teeth. The stator assembly defines a stator envelope in an axial direction extending between axial ends of stator end caps of the stator assembly. The brushless motor further includes a rotor assembly including a rotor core having rotor laminations and defining a central aperture that extends in the axial direction and that receives a shaft, and a position sensor board assembly including position sensors and configured to provide position information of the rotor core to the controller. The rotor assembly and the position sensor board assembly are provided at least partially within the stator envelope.

extrusion process.

Metylen-4-azasteroider.

Extrusion process and extrudate resulting therefrom

Loyalty incentive program using transaction cards

A system and method provide rewards or loyalty incentives to card member customers. The system includes an enrolled card member customer database, an enrolled merchant database, a participating merchant offer database and a registered card processor. The enrolled card member customer database includes transaction accounts of card member customers enrolled in a loyalty incentive program. The enrolled merchant database includes a list of merchants participating in the loyalty incentive program. The participating merchant offer database includes loyalty incentive offers from participating merchants. The registered card processor receives a record for charge for a purchase made with an enrolled merchant by an enrolled card member customer and uses the record of charge to determine whether the purchase qualifies for a rebate credit in accordance with a discount offer from the enrolled merchant. If the purchase qualifies for a rebate credit, the registered card processor provides the rebate credit to an account of the enrolled card member customer. The system provides a coupon-less way for merchants to provide incentive discounts to enrolled customers.

Juice extractor quick connect/disconnect coupling

A quick connect/disconnect coupling for a high-speed appliance such as a juice extractor wherein the driven member, such as a juicer filter basket, is both positively connected for rotation and axially latched to a drive assembly very simply and without any mechanical adjustment.

Agonists of adiponectin

The present invention is related to agonist of adiponectin receptor 1 (AdipoR1) and/or adiponectin receptor 2 (AdipoR2) for the treatment and/or prevention of polycystic ovary syndrome (PCOS).

Composition

Disclosed and claimed are methods for oral contraception, or a hormone replacement therapy, or for treating breast cancer, in a patient in need thereof involving administering to the patient, at a dosage of no greater than 200 μg/day per 70 kg subject, a compound having Formula (I): wherein X in combination with K form a steroidal ring and R 5 is a sulphamate group that has of the formula: wherein each of R 1 and R 2 is H.

Shifting mechanism for a drill press

A transmission for a power tool includes an intermediate shaft and first and second driving gears coupled for co-rotation with the intermediate shaft. The transmission also includes an output shaft having first and second driven gears continuously engaged with the respective first and second driving gears. The transmission further includes a hub coupled for co-rotation with the output shaft, and a collar. The collar is axially movable along the output shaft between a first position in which the collar couples the first driven gear to the hub for co-rotation with the output shaft, and a second position in which the collar couples the second driven gear to the hub for co-rotation with the output shaft.

Slip clutch arrangement for power tool

The invention provides a power tool including an improved slip clutch assembly for transmitting torque from a motor-driven driving member to the rotatably driveable output shaft of the tool. The clutch assembly includes an annular clutch gear around the output shaft. The clutch gear meshes with the driving member and includes circumferentially spaced pockets that correspond to circumferentially spaced, conically-shaped detent depressions in the output shaft. The clutch assembly also includes a plurality of ball members each positioned in one of the pockets in the clutch gear. The ball members are spring-biased toward seated positions in the detent depressions to engage torque transmission between the clutch gear and the output shaft. When subjected to an overload torque, the ball members unseat from the detent depressions with a ratcheting action to disengage torque transmission between the clutch gear and the output shaft.

New 4-(3-oxo-estra-4,9-dien-11 beta-yl)-benzaldehyde oximes, are progesterone receptor modulators useful in female contraception, hormone replacement therapy and treatment of gynecological disorders

Die Erfindung betrifft 11beta-Benzaldoxim-estra-4,9-dien-Derivate für die weibliche Kontrazeption, die bekannte Vorteile der konventionellen Kontrazeption und zusätzliche Vorteile in sich vereinen. DOLLAR A Es werden 11beta-Benzaldoxim-estra-4,9-dien-Derivate der allgemeinen Formel I DOLLAR F1 vorgeschlagen.

9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceutical agents

The invention relates to 9-halogen-(Z) prostane derivatives of formula I ##STR1## in which ##STR2## Z represents the radicals Hal represents a chlorine or fluorine atom, R 1 represents ##STR3## A represents a --CH 2 --CH 2 --, a trans--CH=CH or --C≡C, W represents a free or a functionally modified ##STR4## group, D and E together represent a direct bond or D represents a straight-chain alkylene group with 1-10 C atoms, a branched-chain alkylene group with 2-10 C atoms or an annular alkylene group with 3-10 C atoms, which optionally can be substituted by fluorine atoms, and E represents an oxygen or sulfur atom, a direct bond, a C≡C bond or a --CR 6 =CR 7 group, and R 6 and R 7 are different and mean a hydrogen atom, a chlorine atom or a C 1 -C 4 alkyl group, R 4 represents a free or functionally modified hydroxy, R 5 means a hydrogen atom, an alkyl, a halogen-substituted alkyl, a cycloalkyl or an optionally substituted aryl or a heterocyclic group.

Drawing device

9-halogen prostaglandins

ABSTRACT OF THE DISCLOSURE 9-Halogen prostane derivatives of formula I (I), wherein Hal is a chlorine or fluorine atom in the .alpha. or .beta. -position, R1 is the radical CH20H or -C-OR2 with R2 is a hydrogen atom, an alkyl, cycloalkyl, aryl or heterocyclic radical or R1 is the radical , with R3 is an acid radical or the radical R2 A is a -CH2-CH2-, a trans-CH=CH- or a -C?C- group, W is a free functionally modified hydroxymethylene group or a free or func-tionally modified group, whereln the OH group may be in the .alpha. or .beta. -position, D and E together form a direct bond or D is a straight-chain, branched-chain or cyclic alkylene group wtth 1 to 10 C-atoms, which may be substituted by fluorine atoms, E represents an oxy-gen or sulfur atom, a direct bond, a -C?C- bond or a -CR6=CR7-group, where R6 and R7 are different and are a hydrogen atom, a chlorine atom or a C1-C4-alkyl group, R4 a free or functionally modified hydroxy group, and R5 is a hydrogen atom, an alkyl, an alkenyl, a halogen-substituted alkyl, a cycloalkyl, an aryl or a heterocyclic group or when D and E forms a direct bond an alkenyl group and, where R2 is a hydrogen atom, its salts with physiolog-ically tolerable bases useful as pharmaceuticals having compound effects over material prostaglandins.

Use of estriol for treating climacteric osteoporosis

The invention relates to the use of estriol as the sole active ingredient for the production of a transdermal medicament which continuously releases the active ingredient for the treatment of climacteric osteoporosis. It has been shown according to the invention that estriol, which has up until now been thought ineffective for the treatment of climacteric osteoporosis, develops strong anti-osteoporotic effectiveness upon continuous transdermal application.

6,6-ETHYLENE-15,16-METHYLENE-3-OXO-17.alpha.-PREGN-4-ENE- 21,17-CARBOLACTONES, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM

Abstract 6,6-ethylene-15,16-methylene-3-oxo-17.alpha.-pregn-4-ene-21,17.alpha.-carbolactones of general Formula I (I) wherein is a CC-single of CC-double bond, R1 is a hydrogen atom or a methyl group, R2 is a methyl or ethyl group, and is or

Controlled release pharmaceutical composition

13-ALQUIL-11-BETA-FENIL-GONANOS.

SE DESCRIBEN 13- ALQUIL -11 BETA- FENIL -GONANOS DE LA FORMULA GENERAL I, DONDE: Z, R1, R2, R3 Y R4 TIENEN EL SIGNIFICADO DADO EN LA DESCRIPCION, PRODECIMIENTO PARA SU FABRICACION, PREPARADOS FARMACEUTICOS QUE CONTIENEN COMBINACIONES ASI COMO SU UTILIZACION PARA FABRICACION DE MEDICAMENTOS. LAS NUEVAS COMBINACIONES DE LA FORMULA GENERAL I TIENEN EXCELENTE EFECTIVIDAD ANTIGESTAGENA. 13- RENT -11 BETA- FENIL -GONANOS OF THE GENERAL FORMULA I ARE DESCRIBED, WHERE: Z, R1, R2, R3 AND R4 HAVE THE MEANING GIVEN IN THE DESCRIPTION, PRODUCTION FOR THEIR MANUFACTURE, CONTAINING PHARMACEUTICAL PRODUCTS AS WELL AS USE FOR THE MANUFACTURE OF MEDICINES. THE NEW COMBINATIONS OF THE GENERAL FORMULA I HAVE EXCELLENT ANTIGESTAGEN EFFECTIVENESS.

Estra-1,3,5(10)-triene derivatives, methods of preparing such compounds and pharmaceutical compositions containing them

The invention concerns novel estra-1,3,5(10)-triene amidosulphamates with an R-SO2-O- group in the 3-position, R being an R1R2N- group in which R?1 and R2¿, independently of each other, are a hydrogen atom, an alkyl group with 1 to 5 C-atoms or, together with the N-atom, a polymethyleneimino group with 4 to 6 C-atoms or a morpholino group. The compounds described are suitable for use in hormonal contraception and in climacteric hormone-replacement therapy (HRT), as well as in the treatment of gynaecological and andrological conditions. The compounds described thus only have a low hepatic oestrogenicity. Also described are methods of preparing the compounds described, plus the preparation of pharmaceutical compositions containing them.

Use of biogenic estrogen sulfamates for hormone replacement therapy

The invention relates to the use of biogenic estrogen sulfamates for the ora l discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of gestagens, preferably continuously in the form of an implant or in the form of an intrauterine releasing system (IUD). Estrone sulfamate, estradiol sulfamate or an N-acyl sulfamate of estrone, estradiol or estriol having up to 7 C-atoms in the acyl chain, or a combination comprised of two or more of said active ingredients are used as biogenic estrogen sulfamates.

Method and apparatus for connecting a plurality of battery cells in series or parallel

Methods and systems for selectively connecting a plurality of battery cells in a dual-mode battery pack in series and parallel configurations and/or for individual cell monitoring. A dual-mode battery pack may generally include a housing; a first set of battery cells connected in series; and a second set of battery cells connected in series. The battery pack may also include series connection contacts selectively connectable to the first set of battery cells and to the second set of battery cells and, when engaged, connecting the first set of battery cells and the second set of battery cells in a series configuration; and parallel connection contacts selectively connectable to the first set of battery cells and the second set of battery cells and, when engaged, connecting the first set of battery cells and the second set of battery cells in a parallel configuration.

New 11-benzaldoxime-17beta-methoxy-17alpha-methoxymethyl-estradiene derivatives, processes for their preparation and medicaments containing these compounds

11-benzaldoxime-17beta-methoxy-17alpha- methoxymethylestradiene-derivatives, methods for their production and pharmaceuticals containing these substances

11-Benzaldoxime-oestradiene derivatives of the general formula I <IMAGE> and their pharmaceutically acceptable salts, a process for their preparation and pharmaceutical compositions containing them are described. The described compounds display potent antigestagenic effects with lower glucocorticoid activity.

Method of inducing labour or terminating a pregnancy using a prostaglandin and an antigestagen and packs and preparations suitable therefor

ABSTRACT A method of inducing labour or terminating a pregnancy using a prostaglandin and an antigestagen and packs and preparations suitable therefor . . A method of inducing labour or terminating a pregnancy in a pregnant human or animal female using both a prostaglandin and an antigestagen, and pharma-ceutical packs and preparations suitable for such a method each comprising a prostaglandin and an antigestagen. The prostaglandin is, for example, 16-phenoxy-.omega.-17,18,19,20-tetranor-PGE2-methylsulphonylamide (Sulprostone) and the antigestagen is, for example, 11B -[4-N,N-dimethylamino)-phenyl]-17B-hydroxy-17.alpha.-propynyl-.DELTA.4,9(10)-oestradien-3-one

17alpha fluoroalkyl steroids, method for producing the same and pharmaceutical compositions containing said compounds

9-Halogen prostane derivatives

9-halogen-prostane having the formula (I) wherein Hal represents a chlorine or fluorine atom in position $g(a) or $g(b); R1? represents the rest CH2?OH or the formula (A) with R2? representing a hydrogen atom, an alkyl, cycloalkyl, aryl or heterocyclic rest or R1? represents the rest of formula (B) with R3? representing an acid rest or the rest R2?; A is a group -CH2?-CH2?-, -CH=CH- trans or -C=C-; W is free or functionally transformed hydroxy methylene group or a free or functionally transformed group having the formula (C), the group OH susceptible of being in position $g(a) or $g(b); D and E represent together a direct bound or D represents a straight branched or cyclic chain alkylene group with 1 to 10 atoms of carbon, substituted optionally by fluorine atoms, and E represents oxygen or sulfur, a direction bound, a bound -C=C- or a group -CR6?=CR7?, R6? and R7? being different and representing hydrogen, chlorine or alkyl with 1 to 4 atoms of carbon; R4? is a free or functionally modified hydroxy group; R5? is a hydrogen atom, an alkyl, a halogen-substituted alkyl, a cycloalkyl, an optionally substituted aryl or a heterocyclic group; as well as, if R2? represents a hydrogen atom, the salts thereof with physiologically acceptable bases, the preparation process thereof and the pharmaceutical utilization thereof.

Production of beadlets comprising probiotic compounds

The present invention relates a process of production of beadlets comprising probiotic compounds in a matrix comprising at least one starch and/or starch derivative, to such beadlets and to the use of such specific beadlets in food (for humans and animals) as well as in premixes.

Unsaturated 14,15-cyclopropano-androstanes

The invention relates to new, unsaturated 14, 15-cyclopropano-androstanes of the general formula (I) (see formula I) to their synthesis and to pharmaceutical compositions, containing these compounds. The compounds of formula (I) have gestagenic and/or androgenic activity.

USE OF BIOGENIC ESTROGEN SULFAMATE FOR HORMONE SUBSTITUTION THERAPY

6,6-ethylene-15,16-methylene-3-oxo-17-alpha-pregn-4-ene 21-17 carbolactone, process for their preparation and pharmaceutical compositions containing them

Method of 9-fluorprostaglandine derivatives production

Die Erfindung umfaßt 9-Fluor-prostanderivate der allgemeinen Formel l, worin R 1 den Rest CH 2 OH oder mit R 2 in der Bedeutung eines Wasserstoffatoms, eines Alkyl-, Cycloalkyl-, Aryl- oder heterocyclischen Restes oder R, den Rest mit R 3 in der Bedeutung eines Säurerestes oder des Restes R 2 und A eine -CH 2 -CH 2 - oder cis-CH=CH-Gruppe, B eine -CH 2 -CH 2 -, oder trans-CH=CH- oder eine -C≡C- Gruppe, W eine freie oder funktionell abgewandelte Hydroxymethylengruppe, wobei die OH-Gruppe a- oder ß-ständig sein kann, D und E gemeinsam eine direkte Bindung oder D eine gerad- oder verzweigtkettige Alkylengruppe mit 1-10 C-Atomen, die gegebenenfalls durch Fluoratome substituiert sein kann, E ein Sauerstoff- oder Schwefelatom, eine direkte Bindung, eine -C≡C-Bindung oder eine -CR 6 =CR 7 -Gruppe darstellt, wobei R 6 und R 7 sich unterscheiden und ein Wasserstoffatom, ein Chloratom oder eine Alkylgruppe bedeuten, R 4 eine freie oder funktionell abgewandelte Hydroxygruppe, R 5 ein Wasserstoffatom, eine Alkyl-, eine Halogen-substituierte Alkyl-, eine Cycloalkyl-, eine gegebenenfalls substituierte Aryl- oder eine heterocyclische Gruppe und falls R 2 die Bedeutung eines Wasserstoffatoms hat, deren Salze mit physiologisch verträglichen Basen bedeuten, ihre Herstellung und Verwendung als Luteolytika oder Abortiva.

Pharmaceutical combinations for compensating for a testosterone deficiency in men while simultaneously protecting the prostate

This invention relates to pharmaceutical combinations for compensating for an absolute and relative testosterone deficiency in men with simultaneous prophylaxis for the development of a benign prostatic hyperplasia (BPH) or prostate cancer. The combinations according to the invention contain a natural or synthetic androgen in combination with a gestagen, an antigestagen, an antiestrogen, a GnRH analog, a testosterone-5α-reductase inhibitor, an α-andreno-receptor blocker or a phosphodiesterase inhibitor. In comparison to the combinations according to the invention, any active ingredient by itself cannot achieve the desired goal.

Carboxylic acid derivatives, their production and use

The invention relates to carboxylic acid derivatives of the formula where the radicals have the meanings defined in the description, to the preparation of these compounds and to their use as drugs.

New 14 alpha,17 alpha-bridged oestratriene derivatives

New 14alpha, 17alpha-bridged oestratrienes of formula (I) are claimed. When OR3 is in the alpha-configuration: R1, R2, R3 = H, -CO-R4 or -(CH2)n-CO2H, where n = 1-4. R1 may also be benzyl, 1-8C alkyl or 3-5C cycloalkyl; R4 = an organic gp. with up to 11C atoms. When OR3 is in the beta-configuration: R1, R2, R3 = H or 1-12C acyl; R1 may also be 1-8C alkyl. In both cases, A-B is an etheno or etheno bridging bond. 18 cpds. are specifically claimed, including 3-benzyloxy-14alpha, 17alpha-ethano- 1, 3, 5(10)oestratriene-16alpha, 17beta-diol and 14alpha, 17alpha-ethano -1, 3, 5(10) oestratriene-3, 16alpha, 17beta-triol. Also claimed is a method of preparing (I), e.g. from 3, 16beta, 17beta-triacetoxy-14alpha, 17alpha-ethano-1, 3, 5 (10)-oestratriene-16alpha-carbonitrile. For treating disorders involving oestrogen deficiency, unit oral dose is 0.001-0.05 mg. Solns. for intramuscular injection contain 0.01-1 mg (I) per ml, and vaginal salves contain 0.1-10 mg (I) per 100 ml. For contraception, tablets contain 0.003-0.05 mg (I) and 0.05-0.5 mg of a gestagen.

Multi-stage transmission for a power tool

A multi-stage planetary transmission includes a transmission housing and a first planetary stage at least partially positioned in a transmission housing. The first planetary stage includes a first stage ring gear, a first stage carrier, and a plurality of first stage planet gears supported by the first stage carrier. A motor output pinion is engaged with each of the first stage plant gears. The transmission further includes a second planetary stage positioned downstream of the first planetary stage to receive torque from the first planetary stage and a shift mechanism operable to move the first stage ring gear between a first position, in which the first stage ring gear is rotatably fixed relative to the transmission housing for enabling the first planetary stage, and a second position, in which the first stage ring gear is coupled for co-rotation with the first stage carrier for disabling the first planetary stage.

Estra-1,3,5(10)-triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds

D-homo-(16-ene)-11β-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents

New D-homo-(16-ene)-11β-aryl-4-estrenes of general formula I ##STR1## as well as their pharmaceutically compatible addition salts with acids are described in which X stands for an oxygen atom, the hydroxyimino grouping >N˜OH or two hydrogen atoms, R 1 stands for a hydrogen atom or a methyl group, R 2 stands for an hydroxy group, a C 1 -C 10 alkoxy or C 1 -C 10 acyloxy group, R 11 stands for a fluorine, chlorine or bromine atom, and then R 12 and R 13 together mean an additional bond or R 11 stands for a straight-chain or branched-chain C 1 -C 4 -alkyl radical or a hydrogen atom, and then R 12 and R 13 each mean a hydrogen atom or together mean an additional bond, and R 3 and R 4 have the usual meanings indicated in the description for competitive progesterone antagonists. The invention further relates to a process for the production of new compounds, pharmaceutical preparations containing these compounds, their use for the production of pharmaceutical agents as well as the new intermediate products necessary for the process. The new compounds have a strong affinity to the gestagen receptor and show strong antigestagen as well as antiglucocorticoid, antimineral corticoid and antiandrogenic properties.

(13e)-(8r,11r,12r)-11,15-dihydroxy-16,19-dimethyl-9-oxo-13,18-prostadienoic acids and their salts, their preparation and pharmaceutical compositions

Iibeta-aryl-4-estrenes,process for their production as well as their use as pharmaceutical agents

14,15-cyclopropano steroids of the 19-norandrostane series, method for the production thereof and pharmaceutical preparations containing said compounds

Described are new 14,15-cyclopropano steroids of the 19-norandrostane series of general formula (I) and their pharmaceutically acceptable salts, a process for their production and pharmaceutical preparations that contain these compounds. The compounds are distinguished by hormonal (gestagenic and/or androgenic) activity.

Pharmaceutically active 9-chloroprostaglandins

A 9-chloroprostane of the formula ##STR1## wherein the 9-chlorine atom can be in the α or β-position and R 1 , R 4 , R 5 , A, B, W, D and E are as described hereinafter which are useful as medical agents.

Antigestagenic and antioestrogenic compounds for the introduction of labour and interruption of pregnancy, as well as for the treatment of gynecologic disorders

Power tool with debris collection chute

A power tool (10, fig 1A) comprises a housing assembly including a housing portion and an arm B14 extending upwardly from the housing portion, the arm having an outer surface. A drive unit is supported by the arm, the drive unit being operable to drive a tool element to work on a work piece. A collection assembly is provided, which is operable to collect debris generated by the tool element working on the work piece. The collection assembly includes a collection chute assembly having an inlet C78 and an outlet C82, the collection chute assembly being positionable on the arm to define, between the inlet and outlet, a first path for debris around one side of the outer surface of the arm and a second path for debris around the other side of the outer surface of the arm. Preferably, the chute assembly comprises a first chute member C70 on one side of the arm, and a second chute member C74 on the other side of the arm, the first and second chute members being connectable around the arm. The power tool may be a saw, a miter saw, a sliding saw, or a compound miter saw.

9-halogen-(z)-prostaglandin derivatives, process for manufacturing them, and their use as drugs

9-Halogen-(Z)-prostane derivatives have the formula (I), where Z is one of the residues (a) or (b), Hal is a chorine or fluorine atom in the $g(a) or $g(b) position, R1? is the residue CH2?OH or (c) where R2? is a hydrogen atom or an alkyl, cycloalkyl, aryl, or heterocyclic residue, or R1? is the residue (d) where R3? is an acid residue or the R2? residue, A is a -CH2?-CH2?-, a trans-CH=CH or a -C=C-group, W is a free or functionally modified hydroxymethylene group or a free or functionally modified (e) group, in which the corresponding OH groups can be in the $g(a) or $g(b) position, D and E together represent a direct bond or D is a straight-chain alkylene group with 1-10 C-atoms, a branched-chain alkylene group with 2-10 C-atoms, or a cyclic alkylene group with 3-10 C-atoms, which may, if necessary, be substituted by fluorine atoms, and E is an oxygen or sulphur atom, a direct bond, a -C=C- bond, or a -CR6?=CR7?-group, where R6? and R7? are different and stand for a hydrogen atom, a chlorine atom, or a C1?-C4? alkyl group, R4? is a free or functionally modified hydroxy group, R5? is a hydrogen atom, an alkyl group, a halogen-substituted alkyl group, a cycloalkyl group, a heterocyclic or possibly aryl-substituted group. The invention also concerns the salts of these derivatives with physiologically innocuous bases and their cyclodextrin chlathrates, in the case in which R2? is a hydrogen atom. Also described are the process for manufacturing these derivatives and their pharmaceutical use.

11β-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents

A method of inducing an antigestagenic effect by the administration of compounds of formula I: <IMAGE> (I) wherein, substituents are as defined in the specification.

13 .alpha.-ALKYL-17 .beta.-(3-ACYLOXYPROPYL)-GONANES

ABSTRACT OF THE DISCLOSURE The present invention provides 13 ?-alkylgonanes of the general formula I

Band saw

A hand-held power tool includes a housing having an opening, first and second wheels supported by the housing for rotation about respective first and second parallel axes, a continuous saw blade supported by the first and second wheels, a first guide roller set coupled to the housing proximate a first side of the opening, and a second guide roller set coupled to the housing proximate a second side of the opening. The first and second wheels define respective first and second facing, parallel planes containing the first and second axes. The first and second guide roller sets define respective third and fourth facing, parallel planes that are also parallel to the first and second planes. A first dimension between the first plane and the third plane is less than about 3.3 inches. A second dimension between the second plane and the fourth plane is less than about 3.3 inches.

13 .alpha.-ALKYLGONANES, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM

ABSTRACT The present invention provides a compound of the general formula (I) in which R1 represents a group of the general formula in which RI and RII, which may be the same or dif-ferent, each represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, or RI and RII, together with the nitrogen atom to which they are attached, represent a saturated 5- or 6-membered ring, which may, if desired, contain a further hetero atom, or a corresponding tertiary N-oxide group, or ORIII in which RIII represents a methyl, ethyl, propyl, isopropyl, methoxyphenyl, allyl or-.beta.-dimethylaminoethyl group, R2 represents a hydrogen atom, a methyl group or an ethyl group, R3 represents a group of the general formula -(CH2)n-CH3 in which n represents 0 or an integer from 1 to 4, a group of the general formula -(CH2)n-CH2-ORIV or -(CH2)n-CH2-SRIV in which n represents 0 or an integer from 1 to 5, and RIV represents a hydrogen atom or an alkyl or alkanoyl radical each having from 1 to 4 carbon atoms, a group of the general formula -CH=CH-(CH2)n-ORV in which n represents an integer from 1 to 4, and RV represents a hydrogen atom or an alkyl or alkanoyl radical each having from 1 to 4 carbon atoms, a group of the general formula -C?C-X in which X represents a hydrogen atom or an alkyl radical having from 1 to 4 carbon atoms or a halogen atom, a group of the general formula -(CH2)n-CH2CN in which n represents 0 or an integer from 1 to 3, or a group of the formula -?-CH2Y in which Y represents a hydrogen atom of a group of the general formula ORV in which RV has the meaning given above, R4 represents a hydroxy group or an alkoxy or alkanoyloxy radical each having from 1 to 4 carbon atoms or R3 and R4, together with the carbon atom to which they are attached,represent a group of the formula

Use of estriol for the manufacture of a transdermal therapeutic system for treating climacteric osteoporosis

The invention relates to the use of estriol as a single active agent for the production of a transdermal medicament continuously releasing the active agent for the treatment of climacteric osteoporosis. According ot the invention, it has been shown that estriol, which was formerly regarded as ineffective in treating climacteric osteoporosis, displays a strongly antiosteoporotic effect with continuous transdermal application.

Resilient coupling between inner and outer shaft - has conical rubber section within bearing allowing relative displacement between shafts

The resilient coupling comprises an outer driving shaft supported in bearings in a fixed structure and an inner shaft supported in a single bearing within the outer shaft. The single bearing is arranged at one end of the outer shaft and allows angular displacement of the inner shaft. Each shaft has an end portion projecting beyond the bearings of the outer shaft and beyond the single bearing. The end portions are connected by a resilient coupling transmitting torque to the angularly movable inner shaft.

Modified lupin proteins for the preparation of water dispersible product forms of fat soluble compounds

The present invention relates to a process for the manufacture of a modified lupin protein, which comprises adjusting an aqueous solution or suspension of lupin proteins of native origin having a dry mass content of from 0,1 to 20 % to pH 3 to 9, adding 0,01 to 10 % by weight of a protease, in relation to the dry weight of the lupin protein, incubating the protein solution or suspension at a temperature of from 5 to 70 °C until a degree of hydrolysis of from 1 to 30 % is obtained, and inactivating the protease, to modified lupin proteins obtainable by this process, to compositions containing said lupin proteins together with a fat-soluble active ingredient or colorant, and to the use of said composition for enrichment, fortification and/or coloration of food, beverages, animal feeds, cosmetics or drugs. Further, the invention relates to food, beverage, animal feeds, cosmetics or drugs containing said composition.

Multiphase tablet and process for the preparation thereof

D-homo-(16-en)-11.beta.-aryl-4-estrenes, process for producing them and their use as medicaments

ABSTRACT OF THE DISCLOSURE A new type of D-homo-(16-en)-11.beta.-aryl-4-estrenes having general formula (I), as well as their pharmacologically acceptable addition salts with acids are disclosed. In formula (I), X stands for an oxygen atom, the hydroxyimino grouping > N ~ OH or two hydrogen atoms; R1 stands for a hydrogen atom or a methyl group; R2 stands for a hydroxy group, a C1-C10-alkoxy or C1-C10-acyloxy group; R11 stands for a fluorine, chlorine or bromine atom, in which case R12 and R13 represent together an additional bond, or R11 stands for a straight or branched chain C1-C4alkyl residue or a hydrogen atom, in which case R12 and R13 each represent a hydrogen atom or together represent an additional bond; and R3 and R4 have the usual meaning for competitive progesterone antagonists given in the description. Also disclosed are a process for producing these new compounds, pharmaceutical compositions containing these compounds, their use for producing medicaments and new intermediate products required for carrying out the process. These new compounds have a strong affinity for the gestagen receptor and strong antigestagenous, antiglucocorticoidal, antimineralcorticoidal and antiandrogenous properties.

9-Fluoroprostaglandin derivatives, and use as medicinal agents

9-Fluoroprostane derivatives of Formula I ##STR1## wherein R 1 is CH 2 OH or ##STR2## wherein R 2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R 1 is the residue ##STR3## wherein R 3 is an acid residue or R 2 and A is --CH 2 --CH 2 -- or cis--CH═CH--, B is --CH 2 --CH 2 --, trans--CH═CH-- or --C.tbd.C, W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the α- or β-position, D and E jointly are a direct bond or D is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen or sulfur, a direct bond, --C.tbd.C-- or --CR 6 ═CR 7 -- wherein R 6 and R 7 differ from each other and each is hydrogen, chlorine, or alkyl, R 4 is a free or functionally modified hydroxy group, and R 5 is hydrogen, an optionally substituted aliphatic group, e.g., alkyl or halosubstituted alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group, and, when R 2 is H, physiologically compatible salts thereof with bases, have valuable pharmacological properties, e.g., as luteolytics or abortifacients.

Use of mesoprogestins (modulators of progesterone receptors) as a component for preparation of woman contraceptives

The present invention relates to the use of mesoprogestins for the production of a pharmaceutical for female contraception, to a pharmaceutical preparation for female contraception and to a method of female contraception administering effective amounts of a mesoprogestin in a female desiring contraception. Optionally the mesoprogestin can be used in combination with an estrogen. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention.

Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)

Изобретението се отнася до приложение на мезопрогестини като фармацевтични компоненти за производството на лекарствени средства за хормонозаместваща терапия (ХЗТ) и като компоненти в комбинация с естрогени за производство на лекарствени препарати заХЗТ, както и до съответните ХЗТ методи и до методи за лечение на хормонодефицитни или дисхормононални симптоми. Мезопрогестините се определят като компоненти, които имат едновременно антагонистична иагонистична активност по отношение на прогестероновите рецептори (PR) in vivo. Те стабилизират функцията на PR на междинно ниво като агонисти и антагонисти. Предпочитаните мезопрогестини са J 867, J 912, J 965 и J 1042.

11.beta.-PHENYL-GONANES, THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM

ABSTRACT OF THE DISCLOSURE 13-alkyl-11.beta.-phenyl-gorlanes of general formula 1 (I)

13-alkyl-11beta-phenylgonanes

There are provided 13-alkyl-11beta-phenyl-gonanes of formula I ##STR1## wherein Z is an oxygen atom or N--OH; R 2 is alpha- or beta-position methyl or ethyl; R 1 is selected from heteroaryl radicals, cycloalkyl radicals, cycloalkenyl radicals, aryl radicals, alkenyl radicals, and alkyl radicals where R 2 is in the alpha-position and an ethyl radical where R 2 is in the beta-position; and R 3 and R 4 are selected from one of two different groups of substituent pairs, the group from which the selection is made being determined by the position of R 2 .

Brushless motor for a power tool

Mattress cover assembly

13-alpha-alkyl gonanes, their preparation and pharmaceutical compositions containing them

Cover assemblies for mattresses

A cover assembly for a mattress is provided that includes a first cover and a second cover. The first cover includes a top panel, a bottom panel, and a continuous side panel collectively defining a cavity for enclosing the mattress. The second cover includes a top surface and a bottom surface, with the second cover being positioned over and dimensionally-sized to cover at least the top panel of the first cover. A fastener then connects the second cover to the first cover along the perimeter of the second cover. Methods for marking a mattress are also provided that include the step of marking an indicia indicative of a characteristic of a mattress on the top surface of the second cover of the cover assembly.

15ALPHA, 16ALPHA-METHYLENE-4-OESTREN-17BETA-OLE